We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+2.77%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$403M
AUM Growth
-$119M
Cap. Flow
-$99.2M
Cap. Flow %
-24.64%
Top 10 Hldgs %
53.89%
Holding
40
New
8
Increased
5
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$16.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$11.7M
4
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$11.7M
5
GOSS icon
Gossamer Bio
GOSS
+$10.2M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$15.9M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$15.1M
3
ITOS
iTeos Therapeutics
ITOS
+$11M
4
NTLA icon
Intellia Therapeutics
NTLA
+$10.3M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 86.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
26
Adicet Bio
ACET
$72.8M
$4.37M 1.09%
26,563
– –
SPRY icon
27
ARS Pharmaceuticals
SPRY
$590M
$3.97M 0.99%
128,572
– –
FRLN
28
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$3.27M 0.81%
26,783
-465
-2% -$72.3K
MGNX icon
29
MacroGenics
MGNX
$235M
$3.03M 0.75%
+112,839
New +$3.3M
CSTL icon
30
Castle Biosciences
CSTL
$749M
– –
-100,000
Closed -$6.85M
CVAC
31
DELISTED
CureVac
CVAC
– –
-110,000
Closed -$10.1M
FDMT icon
32
4D Molecular Therapeutics
FDMT
$526M
– –
-150,000
Closed -$6.51M
IMVT icon
33
Immunovant
IMVT
$8.09B
– –
-260,000
Closed -$4.17M
ITOS
34
DELISTED
iTeos Therapeutics
ITOS
– –
-322,794
Closed -$11M
LUNG icon
35
Pulmonx
LUNG
$49.4M
– –
-58,939
Closed -$2.7M
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.25B
– –
-413,061
Closed -$10.1M
OLK
37
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
– –
-200,000
Closed -$7.2M
ORTX
38
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-54,743
Closed -$3.97M
APTO
39
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-3,131
Closed -$8.42M
ITMR
40
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
– –
-273,569
Closed -$6.55M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q2 2021 Portfolio in Review

As of Q2 2021, Ally Bridge Group held 40 positions worth $403M, down 23% from $522M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Ally Bridge Group withdrew a net $99.2M in Q2 2021, closing 11 positions and reducing 7 holdings. Its most notable exit was iTeos Therapeutics, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier.

Against the trend, Ally Bridge Group opened a new position in Nautilus Biotechnolgy worth $15.2M.

  • Ally Bridge Group's largest Q2 2021 buy was Nautilus Biotechnolgy: 1,500,000 shares worth $15.2M.
  • Ally Bridge Group added most to IDEAYA Biosciences in Q2 2021, an estimated $9.87M increase.
  • Ally Bridge Group's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $15.9M.
  • Ally Bridge Group fully exited iTeos Therapeutics in Q2 2021, selling an estimated $11M.
  • Ally Bridge Group's ten largest holdings make up 54% of its $403M portfolio in Q2 2021.
  • Ally Bridge Group opened 8 new positions and closed 11 in Q2 2021.
  • Ally Bridge Group's portfolio value fell 23% quarter-over-quarter to $403M.

Based on Ally Bridge Group's 13F filing for Q2 2021, filed 16 Aug 2021.